Noxopharm investigates Covid-19 treatment

Drug developer Noxopharm is following up on indications that an experimental anti-cancer drug may be effective against the Covid-19 coronavirus. Melbourne’s Hudson Institute of Medical Research has identified anti-inflammatory properties of the experimental drug idronoxil, the active ingredient in the company’s anti-cancer drug candidate Veyonda. Pre-clinical models indicate the drug has the ability to treat…

Details

The reinvention of Australian Industry Content and its ramifications

Australian Manufacturing Forum viewpoint by Mike Kalms Without anything really changing, Australian Industry Content Policy (AICP) is now unalterably different. There have been relatively cosmetic changes to how AICP is described, at what thresholds it applies, and how it might be measured, but none of these constitute wholesale change or any sort of ‘policy re-write’.…

Details

New digital shipbuilding diploma launched

Australia’s first digital shipbuilding course has been launched to support the increased pace and sophistication of naval shipbuilding in Australia. With the federal government letting $90 billion in contracts for patrol boats, frigates and submarines, yards in Perth and Adelaide are increasingly digitally enabled. The BAE Systems yard being enlarged at Osborne in South Australasia…

Details

Titomic in new US defence tie-up

Large-scale additive manufacturing technology company Titomic has linked up with US defence R&D company Triton Systems to validate its Titomic Kinetic Fusion (TKF) technology for US defence projects. The two companies have entered a strategic partnership which aims to develop innovative products and solutions under US defence department grant schemes – the department spends US$60…

Details